EUVIMEDEUVIMED entdecken
Crossref

Tyrosine Amide and Triazaspirocyclic Antimalarials Are Resistant to the Mutant Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL)

Qingmiao Zhou, Jon Kyle Awalt, Jerzy M. Dziekan, Katie Loi, Kate E. Jarman, Jocelyn S. Penington, Anthony T. Papenfuss, Rachael Coyle, Hannah Jagoe, Rebecca C. S. Edgar, Marcus C. S. Lee, Rianne van der Laak und 13 weitere

ACS Infectious Diseases · 13.11.2026

DOI: 10.1021/acsinfecdis.6c00764 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 13.11.2026. Verfasst von Qingmiao Zhou und 24 weiteren Autor:innen. Die Arbeit nennt 58 Literaturangaben. Gefördert von: Howard Hughes Medical Institute, National Health and Medical Research Council, Medicines for Malaria Venture.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tyrosine amide and triazaspirocyclic chemotypes were identified via high-throughput screening against P. falciparum parasites. Chemical synthesis confirmed potently active stereoisomers for both hit classes. Whole-genome sequencing of resistant lines, combined with pooled resistance barcoding, revealed distinct mutations in the cyclic amine resistance locus (PfCARL) and the UDP-galactose transporter (PfUDP), two ER transmembrane proteins previously associated with resistance to the clinical candidate KAF156. Live-cell thermal proteome integral solubility assays suggest that these compounds target proteins connected with ER-mediated trafficking, supporting the role of PfCARL and PfUDP as multidrug resistance loci rather than direct targets. Both chemotypes disrupted protein export, arrested parasites from late ring-to-early trophozoite stages, and inhibited liver schizont and gamete development. In addition, both tyrosine amide and triazaspirocyclic analogs exhibited high solubility and metabolic stability, highlighting their promise for future development as next-generation multistage antimalarials.

Förderung

  • Howard Hughes Medical Institute
  • National Health and Medical Research Council
  • Medicines for Malaria Venture
  • China Scholarship Council
  • Walter and Eliza Hall Institute of Medical Research

Zitieren

APA

Zhou, Q., Awalt, J. K., Dziekan, J. M., Loi, K., Jarman, K. E., Penington, J. S., Papenfuss, A. T., Coyle, R., Jagoe, H., Edgar, R. C. S., Lee, M. C. S., Laak, R. V. D., Bolscher, J. M., Bronkhorst, A. W., White, J. M., Famodimu, M. T., Delves, M. J., Chenu, E., Duffy, J., …, & Sleebs, B. E. (2026). Tyrosine Amide and Triazaspirocyclic Antimalarials Are Resistant to the Mutant Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL). ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.6c00764

Vancouver

Zhou Q, Awalt JK, Dziekan JM, Loi K, Jarman KE, Penington JS, et al. Tyrosine Amide and Triazaspirocyclic Antimalarials Are Resistant to the Mutant Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL). ACS Infectious Diseases. 2026. doi:10.1021/acsinfecdis.6c00764

BibTeX
@article{Zhou2026,
  author = {Zhou, Qingmiao and Awalt, Jon Kyle and Dziekan, Jerzy M. and Loi, Katie and Jarman, Kate E. and Penington, Jocelyn S. and Papenfuss, Anthony T. and Coyle, Rachael and Jagoe, Hannah and Edgar, Rebecca C. S. and Lee, Marcus C. S. and Laak, Rianne van der and Bolscher, Judith M. and Bronkhorst, Alfred W. and White, Jonathan M. and Famodimu, Mufuliat T. and Delves, Michael J. and Chenu, Elodie and Duffy, James and Baud, Delphine and Brand, Stephen and Jackson, Paul F. and Cowman, Alan F. and Dans, Madeline G. and Sleebs, Brad E.},
  title = {Tyrosine Amide and Triazaspirocyclic Antimalarials Are Resistant to the Mutant Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL)},
  journal = {ACS Infectious Diseases},
  year = {2026},
  doi = {10.1021/acsinfecdis.6c00764}
}
Kostenlos starten →